KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short-Term Debt issuances (2021 - 2023)

Pacira BioSciences has reported Short-Term Debt issuances over the past 3 years, most recently at -$149.5 million for Q4 2023.

  • Quarterly results put Short-Term Debt issuances at -$149.5 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Sep 2024 was -$149.5 million (changed N/A YoY), and the annual figure for FY2025 was $101.0 million, changed.
  • Short-Term Debt issuances for Q4 2023 was -$149.5 million at Pacira BioSciences, down from $149.6 million in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for PCRX hit a ceiling of $363.8 million in Q4 2021 and a floor of -$149.5 million in Q4 2023.